Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTG201 and Nivolumab in Relapsed Malignant Pleural Mesothelioma
NCT04013334Phase 2Unknown
- Sponsor
- Momotaro-Gene Inc.
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of MTG201 in malignant pleural mesothelioma (MPM), sponsored by Momotaro-Gene Inc.. Status: unknown.
02
Drugs
MTG201
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04013334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013334.